in our other reports will be successfully commercialized and their use reimbursed, or will enhance our market value; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; or that the Company will not be adversely affected by risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.
Copyright 2013 Cardium Therapeutics, Inc. All rights reserved.
Cardium Therapeutics®, Generx®, Excellagen®, LifeAgain®, BlueMetric™, Decision Rule Adaption™, ADAPT™, Angionetic Therapeutics™, Activation Therapeutics™, MedPodium® and Nutra-Apps® are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company. Other trademarks belong to their respective owners.
Cardium Therapeutics, Inc.Selected Condensed Consolidated Results of OperationsThree months ended September 30,Nine months ended September 30,2013201220132012Product sales$Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Related medicine technology :1
39,241Cost of goods sold(288,522)(3,640)(977,912)(15,191)Gross profit183,0441,949677,43024,050Operating expensesResearch and development(315,178)(508,342)(1,566,988)(2,097,675)Selling, general and administrative(1,636,871)(1,389,731)(5,258,129)(4,358,706)Loss from operations(1,769,0
. Unusual Trading Activity In Cardium Common Stock2
. Cardium Reports On Potential Use Of Excellagen To Repair Prenatally Diagnosed Birth Defects Using Mesenchymal Stem Cells3
. Cardium Announces New Excellagen FDA 510(k) Submission Based On Expanded Structural And Functional Properties4
. Cardium Reports On New Excellagen Distribution Agreement With AvKARE For Veterans Hospitals And Other Governmental Medical Facilities5
. Cardium Completes Preferred Stock Financing6
. Cardium Announces Reverse Stock Split7
. Cardium Announces Initial Voting Results And Temporary Adjournment of Annual Meeting To Be Reconvened On June 21, 20138
. Cardium Presents First Quarter 2013 Financial Results And Reports On Recent Developments9
. Cardium Announces Generx Publication In Molecular Therapy10
. Cardium Announces Excellagen Presentation at the Symposium on Advanced Wound Care Spring 2013 Meeting11
. Cardium Presents Year-End 2012 Financial Results And Recent Developments